SENL 103
Alternative Names: SENL-103Latest Information Update: 19 Jan 2024
At a glance
- Originator Hebei Senlang Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Multiple myeloma
Most Recent Events
- 09 Dec 2023 Updated efficacy and adverse events data from a clinical trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 21 Aug 2023 Phase-0 for Multiple myeloma (Second-line therapy or greater) in China (IV, Infusion) (NCT06067581)